Patient-Derived Xenograft - PDX Models

Over 3000 clinically relevant PDX models that truly mimic human disease.

Leverage the World’s Largest Collection of Highly-Characterized PDX Models

Patient-derived xenografts - PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population.

PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.

Browse PDX Models By Indication

HuBase™ PDX Model Database

Extensive characterization data in our searchable PDX model database, HuBase™, include: RNAseq of over 1,500 models, whole exome sequencing of over 680 models, histology, growth kinetics, and SoC and investigative treatment data.

PDX Model Largest Sub-Collections

Browse HuBase Database

The HuKemia® Blood Cancer PDX Collection:

Evaluate blood cancer therapeutic candidates with validated, stable, truly patient representative leukemia models.

HuKemia is Crown Bioscience’s collection of validated blood cancer PDX models, fully annotated with patient information, diagnosis, and clinical treatments. These models have been fully quality controlled by our pathologists and are available with genotyping and phenotyping data.

Advantages of the HuKemia Blood Cancer PDX Collection

Crown Bioscience’s validated and well-characterized HuKemia models provide many advantages:

Well-established models that have been used in over 100 preclinical studies, and are therefore a tried and tested approach for assessing preclinical efficacy
Derived from patients treated with today's clinical therapeutics, including SOC targeted therapies and immunotherapeutics
Present as stable disease that is transferable through passages, meaning results are highly reproducible across studies
Overcome limitations with CDX models for systemic diseases. When utilizing CDX models, it can be highly challenging to detect the leukemic cells in the blood, limiting studies to only monitoring survival
Can be repeatedly challenged to mimic clinical therapy and the emergence of resistance, which means that models of resistance can be created for testing next-generation drugs
Optional ex vivo assays to leverage access to fresh tumor samples for all AML and ALL models, enabling the assessment of efficient combination and dosing regimens. An illustration of the HuKemia study design followed by ex vivo workflow is shown below

HuKemia Study Design

EX vivo assay

PDX models for blood cancer are historically very challenging to produce, due to their low take rate in vivo. We overcame these challenges to develop a unique collection of AML and ALL PDX models to better support your preclinical research.

Derived directly from patient bone marrow aspirate, our PDX models better reflect the heterogeneity of leukemia. The models present as stable disease and are transferable through passage. This provides highly reproducible results and availability for repeated studies.

Explore Our Collection

Blood Cancer PDX Characteristics:

Stable models with typical leukemia symptoms and eventual mortality, truly representative of the human condition.Progress targeted agents by choosing PDX models with patient-relevant mutationse.g. IDH2 mutation, FLT3-ITD(+), BCR/ABL(+).Explore extensive model charcterization for pathology, growth characteristics, and response to standard of care and experimental agents.Search for models to meet you research needs through genetic and genomic annotations. Models are charcterized for gene expression, gene copy number, mutations, and fusions.

Access the HuBase Model Database

Log in to explore Crown Bioscience's well-characterized Patient-Derived Xenograft's through our searchable database. Access genomic, molecular, and phenotypic data including tumor growth curves, standard of care response, histopathology data, and patient information on the worlds largest collection

Browse or search our collection to access patient information and model specific characteristics.

Search PDX genomic information e.g. RNAseq gene expressions data and WES gene copy number data for MET amplification.

Key Benefits:

Find your interest based on genetic background and response to treatment.
Test novel therapeutic uses for your existing molecules in over 2,500 models across more than thirty cancer types.
Start Mouse Clinical Trials immediately, with our PDX model collection consisting of colorectal, esophageal, gastric, head and neck, liver, lung, ovarian, pancreatic cancer, melanoma, sarcoma, and more.
Discover a PDX model for underrepresented indications, including GIST and prostate cancer.
Use ALL and AML stable PDX models with typical leukemia symptoms and eventual mortality, truly representative of the human condition.
Progress your targeted therapy with a unique model of specific disease pathways such as RET, ALK, EGFR, MET, IDH, RSPO, and HER2.
Start your study without delay across our global operational sites.

PDX Mouse Clinical Trial

Moving into Clinical Trials with More Confidence

PDX Mouse Clinical Trials offer a unique advantage for oncology drug developers by providing:

Better Clinical Translation: PDX models closely mimic human tumor biology, maintaining key features such as the genetic and phenotypic characteristics of patient tumors, leading to more accurate predictions of clinical outcomes.
Predictive Biomarker Discovery: These models help identify biomarkers for patient stratification, enabling more personalized treatment strategies and increasing the likelihood of clinical trial success.
Exploration of New Indications: PDX models allow for the evaluation of therapies across diverse tumor types, uncovering potential new therapeutic applications and expanding indications.
Deeper Drug Response Insights: Gain a deeper understanding of drug efficacy, mechanisms of action (MoA), and resistance mechanisms. PDX models are invaluable for optimizing drug combinations and reducing attrition in clinical development.

Figure. A representative PDX Mouse Clinical Trial Design

For oncology drug discovery teams, Crown Bioscience offers unmatched expertise in PDX mouse clinical trials (MCTs) to accelerate clinical translation and reduce attrition rates.

We leverage the world’s largest PDX model library—over 2,500 models across 30+ indications—ensuring accurate representation of patient heterogeneity.
Our 500+ live PDX models allow for fast-track services, providing shorter timelines and faster results to meet urgent project needs.
Our patented NGS-QC method upholds high quality standards by addressing model misidentification and contamination.
Specializing in PDX biomarker testing and data interpretation, we provide precise analysis even in complex tumor environments.
Our bioinformatics team, backed by peer-reviewed publications, supports every step from trial design to data analysis, delivering actionable insights.

Crown Bioscience offers end-to-end support, replicating clinical trial conditions preclinically to enhance success rates, reduce costs, and speed up drug development. With 12+ years of experience and 300+ successful MCT projects, we are your trusted partner from preclinical to clinical stages.

Learn More